Zenlabs Ethica reported a net loss of Rs 193.56 lakh for FY26, a sharp decline from the previous year's profit. The loss was primarily driven by a Rs 207.81 lakh exceptional write-off following the Reserve Bank of India’s cancellation of the company’s NBFC registration. Amid this transition, the firm has appointed V Nexxtra Lifesciences as an exclusive distributor to streamline sales. Shareholders must now monitor the management's efforts to fix regulatory non-compliance issues and improve operational efficiency to return to profitability.
Zenlabs Ethica Reports FY26 Loss Following Major Business Restructuring
- FY26 Net Loss: Rs 193.56 lakh (down from Rs 26.92 lakh profit in FY25)
- Exceptional Write-off: Rs 207.81 lakh due to NBFC license cancellation
Reader Takeaway: New exclusive distributor appointed; investors should watch for turnaround execution and resolution of regulatory compliance gaps.
What just happened
Zenlabs Ethica Ltd has released its 33rd Annual Report for FY 2025-26, disclosing a significant shift from profitability to a net loss of Rs 193.56 lakh. The total income fell to Rs 4,710.66 lakh compared to Rs 5,147.05 lakh in the previous fiscal year. The primary driver of the bottom-line decline was a substantial exceptional item of Rs 207.81 lakh recorded during the period.
Why this matters
The reported loss is directly linked to the Reserve Bank of India’s order from November 7, 2025, which cancelled the company’s Non-Banking Financial Company (NBFC) registration. This regulatory action forced the firm to discontinue its NBFC operations and write off assets inconsistent with its remaining business model. The company is now in a critical transition phase as it attempts to realign its core operations.
What changes now
To stabilize its operations, the company signed a deal on August 8, 2026, with V Nexxtra Lifesciences. Under this agreement, V Nexxtra becomes the sole and exclusive distributor for Zenlabs Ethica’s entire product portfolio. Management is now prioritizing cost rationalization, supply chain optimization, and the introduction of higher-margin products to recover cash flows.
Risks to watch
Audit reports have raised concerns over corporate governance, specifically non-compliance with the Companies Act regarding Independent Director appointments and SEBI listing regulations on website disclosures. These governance gaps and the ability to execute the new distribution strategy are primary risks for investors to monitor in the coming quarters.
What to track next
Investors should track the company's progress in resolving the identified audit non-compliances and the performance metrics of the new distribution arrangement. Successful implementation of cost-cutting measures will be vital for the company to reverse its recent financial losses.